Complementary and alternative medicines in the treatment of dementia - An evidence-based review

被引:22
作者
Diamond, BJ
Johnson, SK
Torsney, K
Morodan, J
Prokop, BJ
Davidek, D
Kramer, P
机构
[1] William Paterson Univ, Dept Psychol, Wayne, NJ USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA
[3] Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA
关键词
D O I
10.2165/00002512-200320130-00003
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Alternative medicines may have potential beneficial results in treating certain forms of dementia and related symptoms, as well as slowing disease progression. Alternative medicines may ameliorate disturbances in cognition, mood, sleep and activities of daily living. Primary mechanisms of action include modifications in neurotransmitter synthesis, inhibition of neurotransmitter reuptake and enzyme-induced neurotransmitter breakdown, antioxidant and anti-platelet activity, enhanced blood flow and glucose metabolism. Adverse events can include cardiovascular, gastrointestinal, mood, autonomic and dermatologic effects. However, adverse events, when reported represent, a small percentage of treated groups and direct links between adverse events and alternative therapies are tenuous. Many studies of alternative medicines in dementia are inconclusive and characterised by methodological deficiencies such as small sample sizes and inadequate controls. If alternative medicines can be shown to be efficacious using more rigourous experimental designs, both consumers and clinicians could avail themselves of a wider range of pharmacological substances that may offer the advantage of being better tolerated and exhibiting safer therapeutic margins than some allopathic medicines. While a number of complementary interventions have shown both strengths and weaknesses, huperzine A, levacecarnine and EGB 761, based on the overall quality of the studies, identified mechanisms of activity and safety profiles merit further examination in controlled clinical outcome studies.
引用
收藏
页码:981 / 998
页数:18
相关论文
共 118 条
[1]   In vivo regulation of peripheral-type benzodiazepine receptor and glucocorticoid synthesis by Ginkgo biloba extract EGb 761 and isolated ginkgolides [J].
Amri, H ;
Ogwuegbu, SO ;
Boujrad, N ;
Drieu, K ;
Papadopoulos, V .
ENDOCRINOLOGY, 1996, 137 (12) :5707-5718
[2]   Herbal medicines and perioperative care [J].
Ang-Lee, MK ;
Moss, J ;
Yuan, CS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02) :208-216
[3]  
[Anonymous], 2000, TASK FORCE DSM 4 DIA
[4]  
ARRIGO A, 1985, EFFECTS GINKGO BILOB
[5]   Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia:: The results of a double-blind, placebo-controlled trial with Melissa [J].
Ballard, CG ;
O'Brien, JT ;
Reichelt, K ;
Perry, EK .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (07) :553-558
[6]   INFLUENCES OF GINKGO-BILOBA ON CYCLOSPORINE-A INDUCED LIPID-PEROXIDATION IN HUMAN LIVER-MICROSOMES IN COMPARISON TO VITAMIN-E, GLUTATHIONE AND N-ACETYLCYSTEINE [J].
BARTH, SA ;
INSELMANN, G ;
ENGEMANN, R ;
HEIDEMANN, HT .
BIOCHEMICAL PHARMACOLOGY, 1991, 41 (10) :1521-1526
[7]  
BIRKS J, 2003, COCHRANE COLLARBORAT
[8]  
BOOKER D, 1997, BR J CLIN PSYCHOL, V36, P287
[9]   CEREBROSPINAL-FLUID S-ADENOSYLMETHIONINE IN DEPRESSION AND DEMENTIA - EFFECTS OF TREATMENT WITH PARENTERAL AND ORAL S-ADENOSYLMETHIONINE [J].
BOTTIGLIERI, T ;
GODFREY, P ;
FLYNN, T ;
CARNEY, MWP ;
TOONE, BK ;
REYNOLDS, EH .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (12) :1096-1098
[10]  
BRAILOWSKY S, 1992, EFFECTS GINKGO BILOB, P95